

## Olaptesed pegol sodium

Cat. No.:	HY-160041A
Target:	CXCR
Pathway:	GPCR/G Protein; Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

Olaptesed pegol (sodium)

### BIOLOGICAL ACTIVITY

Description	Olaptesed pegol sodium A pegylated-based L-oligoribonucleotide aptamer targeting CXCL12. Olaptesed pegol sodium neutralizes CXCL12, and CXCL12 inhibition mobilizes chronic lymphocytic leukemia cells into the circulation and prevents their homing into the protective microenvironment <sup>[1]</sup> .
IC <sub>50</sub> & Target	CXCL12 <sup>[1]</sup>

### REFERENCES

[1]. Steurer M, Montillo M, Scarfò L, Mauro FR, Andel J, Wildner S, Trentin L, Janssens A, Burgstaller S, Frömmling A, Dümmler T, Riecke K, Baumann M, Beyer D, Vauléon S, Ghia P, Foà R, Caligaris-Cappio F, Gobbi M. Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia. *Haematologica*. 2019 Oct;104(10):2053-2060.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA